Devic disease is autoimmune attack on optic nerveThe Detroit NewsAntibodies show up in her blood work. She is about to undergo two treatments, two weeks apart, of rituximab, hopefully killing the antibodies. What little information I have found online …
To your good health: Devic disease is autoimmune attack on optic nerveSt. Augustine RecordAntibodies show up in her bloodwork. She is about to undergo two treatments, two weeks apart, of rituximab, hopefully killing the antibodies. What little informat…
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial ResultsBusiness Wire (press release)The recommendation followed a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progressio…
MedscapeIdelalisib Combo Rings Bells in Relapsed CLLMedscapeThat drug is idelalisib, a PI3 kinase delta isoform-specific inhibitor. The study by Furman and colleagues was a randomized, placebo-controlled, double-blind trial of rituximab plus placebo vs…
Infinity Announces Promotion of David A. Roth to Chief Medical OfficerMarketWatchAn investigator-sponsored Phase 1b, open-label study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoclonal antibody t…
Devic Disease Is Autoimmune Attack on Optic Nerve; An Exercise Alternative?Valley NewsAntibodies show up in her bloodwork. She is about to undergo two treatments, two weeks apart, of rituximab, hopefully killing the antibodies. What little information …
|
Pharmacyclics, Inc. (PCYC) news: Pharmacyclics: Facts Behind $10B Market Cap
Seeking Alpha To date, first-line treatment has usually consisted of Roche’s (OTCQX:RHHBY) monoclonal antibody Rituxan (rituximab) – which is directed against the CD20 antigen found on B lymphocytes – combined with a multi-agent chemotherapy regimen, most often … |
PR Web (press release) |
ECOG-ACRIN Opens Clinical Trial Investigating Ibrutinib-Rituximab …
PR Web (press release) Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Share on Twitter Share on Facebook Share on Google+ Share … |
Immune drug helps patients with frequently relapsing kidney diseaseNephrologyNews.comRituximab can effectively and safely prevent recurrences and reduce the need for immunosuppression in frequently-relapsing idiopathic nephrotic syndrome, according to …
Biologics and Biosimilars World MarketsSacramento Bee… 6.43.4 Genotropin (somatropin) 231 6.43.5 Herceptin (trastuzumab) 232 6.43.6 Humira (adalimumab) 232 6.43.7 Neulasta (pegfilgrastim) 233 6.43.8 Neupogen (filgrastim) 233 6.43.9 Remicade (inflixim…